A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2484-2492

  Dickson, Mark A ^a   Carvajal, Richard D ^a   Merrill Jr , Alfred H ^b   Gonen, Mithat ^a   Cane, Lauren M ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; SAFINGOL; SPHINGOSINE KINASE 1;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; HUMAN; HYPONATREMIA; LIVER METASTASIS; LUNG METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; LYMPHOPENIA; LYSOPHOSPHOLIPIDS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SPHINGOSINE; TREATMENT OUTCOME;

EID: 79954625512     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2323     Document Type: Article

References (25)

1. Pitman MR, Pitson SM. Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr Cancer Drug Targets 2010;10:354-67.
2. Cuvillier O, Ader I, Bouquerel P, Brizuela L, Malavaud B, Mazerolles C, et al. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 2010;3:53-65.
3. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004;206:169-80. (Pubitemid 38317287)
4. Olivera A, Kohama T, Tu Z, Milstien S, Spiegel S. Purification and characterization of rat kidney sphingosine kinase. J Biol Chem 1998;273:12576-83. (Pubitemid 28240634)
5. Kedderis LB, Bozigian HP, Kleeman JM, Hall RL, Palmer TE, Harrison SD Jr, et al. Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam Appl Toxicol 1995;25:201-17.
6. Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC, et al. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy 2009;5:184-93.
7. Hoffmann TK, Leenen K, Hafner D, Balz V, Gerharz CD, Grund A, et al. Antitumor activity of protein kinase C inhibitors and cisplatin in human head and neck squamous cell carcinoma lines. Anticancer Drugs 2002;13:93-100. (Pubitemid 34169532)
8. Schwartz GK, Jiang J, Kelsen D, Albino AP. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 1993;85:402-7. (Pubitemid 23073160)
9. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000;92:1897-909. (Pubitemid 32036920)
10. Schwartz GK, Ward D, Saltz L, Casper ES, Spiess T, Mullen E, et al. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 1997;3:537-43. (Pubitemid 27211830)
11. Vessey DA, Kelley M, Zhang J, Li L, Tao R, Karliner JS. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J Biochem Mol Toxicol 2007;21:273-9. (Pubitemid 350006284)
12. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. (Pubitemid 36962641)
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
14. Morales PR, Dillehay DL, Moody SJ, Pallas DC, Pruett S, Allgood JC, et al. Safingol toxicology after oral administration to TRAMP mice: demonstration of safingol uptake and metabolism by N-acylation and N-methylation. Drug Chem Toxicol 2007;30:197-216. (Pubitemid 47026913)
15. Sullards MC, Allegood JC, Kelly S, Wang E, Haynes CA, Park H, et al. Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: "inside-out" sphingolipidomics. Methods Enzymol 2007;432:83-115.
16. Gonen M. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in phase I trials. Contemp Clin Trials 2005;26:131-40. (Pubitemid 40693603)
17. Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE, et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med 2005;201:49-54. (Pubitemid 40130083)
18. Alvarez SE, Milstien S, Spiegel S. Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab 2007;18:300-7. (Pubitemid 47531961)
19. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009;325:1254-7.
20. Edsall LC, Spiegel S. Enzymatic measurement of sphingosine 1-phosphate. Anal Biochem 1999;272:80-6. (Pubitemid 29343385)
21. Caligan TB, Peters K, Ou J, Wang E, Saba J, Merrill AH Jr. A highperformance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples. Anal Biochem 2000;281:36-44. (Pubitemid 30324339)
22. Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem 1997;121:969-73. (Pubitemid 27236918)
23. Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 2007;21:1202-9. (Pubitemid 46495709)
24. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316:295-8. (Pubitemid 46633109)
25. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 2008;102:669-76. (Pubitemid 351457860)